- In July 2024, researchers at the Australian Institute for Bioengineering and Nanotechnology (AIBN) developed a diagnostic device that detects early lung cancer signs using sugar molecules. This device, utilizing a drop of blood, identifies extracellular vesicles (EVs) on lung cancer cells. By targeting these sugars, clinicians can identify small lung nodules, enabling early detection before the disease spreads
- In January 2024, scientists created a new method for delivering smart insulin via capsules or even chocolate. Encapsulated in nano-carriers, these particles are 1/10,000th the width of a human hair and offer precise insulin delivery. This rapid, targeted method enhances insulin absorption, improving treatment efficiency and offering a promising solution for diabetes management
- In March 2021, PACIRA Biosciences, Inc. received FDA approval for EXPAREL, a new injectable drug for pediatric patients. EXPAREL, a bupivacaine liposome formulation, provides extended pain relief after surgery without the need for opioids. This approval marks a significant milestone in managing postoperative pain in children while minimizing the risks associated with opioid use
- In March 2021, Jazz Pharmaceuticals announced an expansion for Vyxeos (Daunorubicin and Cytarabine) in treating secondary acute myeloid leukemia (AML). This approval enables the use of Vyxeos in patients with secondary AML, a disease that arises from prior blood disorders or chemotherapy, offering an advanced treatment option to improve outcomes for these high-risk patients
- In February 2021, an interdisciplinary team at Northern Arizona University, in collaboration with U.S. partners, advanced nanotechnology to improve vaccine delivery. This research aims to enhance vaccine efficacy by creating more efficient delivery systems. The development of such technologies holds promise for improving vaccine distribution, particularly in hard-to-reach areas and for addressing emerging diseases
